Isabella Ciccone, Content Associate, NeurologyLive®, has been with the team since September 2022. Follow her on X @iciccone7 or email her at [email protected]
In honor of National Sleep Awareness Week, a group of experts in the care of patients with sleep disorders—Wendy Troxel, PhD; Garth Whiteside; Milena Pavlova, MD; Ronald Gavidia, MD, MS; Renee Shellhaas, MD, MS, FAES—shared their perspectives on hot topics of treatment and management in sleep medicine.
Jeffery Neul, MD, PhD, director of the Vanderbilt Kennedy Center, and professor of pediatrics at Vanderbilt University Medical Center, shared his reactions and thoughts to the approval of trofinetide.
In honor of Brain Awareness Week, a group of experts in the care of patients with neurological conditions—Ronald C. Petersen, MD, PhD; Brian Grosberg, MD, FAHS; James Beck, PhD; Michael Levy, MD, PhD; Stanley H. Appel, MD —shared their perspectives on hot topics of treatment and management in neurology.
Published findings showed that narcolepsy has a significant impact on social relationships in adolescents, thus suggesting that structured routine for assessing social health is a vital first step for treatment.
Omar Al-Louzi, MD, director of the Visual Outcomes Laboratory at Cedars Sinai, provided his clinical perspective on role of imaging and viral infections in patients with MS at the 2023 ACTRIMS forum.
Despite higher baseline scores, Expanded Disability Status Scale scores remained stable over time in Black patients treated with ocrelizumab for multiple sclerosis.
The therapy, marketed as Daybue, is the first therapy indicated for Rett syndrome with supporting data from the pivotal phase 3 LAVENDER study.
Literature reveals an inconsistency in sex differences between women and men, among individuals living with dementia with Lewy bodies and their caregivers.
The phase 2b trial investigating SciSparc’s SCI-110 for Tourette syndrome was recently granted approval to proceed by the Israeli Ministry of Health.
Expression of CD16 and activation markers in natural killer and natural killer-T cells may be responsible for the escalating autoimmune activity in NMOSD.
A group of experts in the care of patients with multiple sclerosis—Marisa McGinley, DO; Farrah Mateen, MD, PhD; Laura Piccio, MD, PhD; Robert Zivadinov, MD, PhD; and Bruce Cree, MD, PhD, MAS, FAAN—shared their perspectives on hot topics of treatment and management from the 2023 ACTRIMS Forum.
The international study on genetic testing and counseling, PD GENEration, is currently at the halfway mark of its goal of 15,000 participants.
Rajiv Jain, PhD, post-doctoral associate, department of clinical neurosciences, University of Calgary, talked about his presentation on T-bet+ memory B-cells in multiple sclerosis at the 2023 ACTRIMS Forum.
Newly approved lab-based blood assessing traumatic brain injury rules out the need for CT scan and eliminates wait time at hospitals.
Svetlana P. Eckert, MD, clinical assistant professor of neurology at University at Buffalo, talked about Evusheld as a preventive approach to COVID-19 infections in multiple sclerosis at the 2023 ACTRIMS Forum.
Nine of the 10 participants with NMOSD included in the case series have remained relapse-free after switching to satrlizumab from previous therapy.
Of 2 patient fatalities in the analysis, one was unvaccinated and treated with nonconventional therapies for COVID-19 and the other had a history of deep venous thrombosis and was complicated by pulmonary embolism.
Bruce Cree, MD, PhD, MAS, FAAN, clinical research director of the UCSF Multiple Sclerosis Center provided insight on 2 post-hoc analyses of the N-MOmentum trial for NMOSD that were presented at 2023 ACTRIMS Forum.
Three of 4 patients withdrew from their previous enzyme replacement therapy following treatment with AT845 gene therapy.
As a recap from ACTRIMS 2023, get caught up on some of the latest news in multiple sclerosis as the NeurologyLive® team shares some of our data updates.
A group of experts in the care of patients with rare diseases—Emma Ciafaloni, MD, FAAN; Martina Bebin, MD, MDA; Timothy Miller, MD, PhD; George Small, MD; Bruce Cree, MD, PhD, MAS, FAAN—shared their perspectives on hot topics of treatment and management.
The wearable device received its original FDA go-ahead in 2019, and has since demonstrated effectiveness in preventive and acute care for migraine treatment in adolescents and adults.
In recognition of Rare Disease Day, the NeurologyLive® team offered an extensive update on the state of care and treatment for a few rare neurological diseases, including Pompe disease, Rett syndrome, among others.
A survey showed that 69% of patients with neuromyelitis optica spectrum disorders reported lost income because of hospital visits related to disease relapse.
Results from the open-label SAkuraMoon study show consistent relapse freedom in satralizumab-treated patients with aquaporin-4-IgG-seropositive NMOSD.
A preclinical assessment of evobrutinib showed it demonstrated superior efficacy in targeting compartmentalized neuroinflammation in multiple sclerosis compared with anti-CD20 treatment.
An analysis of patients with MOGAD showed that only 50% of those treated with various immunotherapies over a long-term period maintained relapse-free status.
Secondary findings from a phase 3 study demonstrate a significant decrease in new T1 enhancing lesions and new enlarging hyperintense T2 lesions in patients with multiple sclerosis undergoing glatiramer acetate depot treatment.
Majority of patients with relapsing multiple sclerosis demonstrated achieving and maintaining no evidence disease activity after being treated with ublituximab.
Gregory Day, MD, MSc, MSCI, FAAN, a neurologist at Mayo Clinic in Jacksonville Florida, talked about the current state of treating autoimmune encephalitis and the significance of the ExTINGUISH trial.
